Operator: Good morning, and welcome to the Johnson & Johnson Third Quarter 2013 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections you may disconnect at this time.
I would now like to turn the conference call over to Johnson & Johnson, you may begin.
Louise Mehrotra - VP, IR: Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson and it is my pleasure this morning to review our business results for the third quarter of 2013.
Joining me on the call today are, Dominic Caruso, Vice President, Finance and Chief Financial Officer and Michel Orsinger, Worldwide Chairman, DePuy Synthes Companies.
A few logistics before we get into the details. This review is being made available to a broader audience via a webcast accessible through the Investor Relations section of the Johnson & Johnson website.
I'll begin by briefly reviewing highlights of the third quarter for the Corporation and highlights for our three business segments.
Following my remarks, Michel will provide an update on our DePuy Synthes business and the progress made on our near-term priority of successfully integrating Synthes. Please note the presentations that accompany Michel's remarks is available on our website. Next, Dominic will provide some additional commentary on the financial results and guidance for 2013. We will then open the call to your questions.
We expect the call to last approximately 90 minutes. Included with the press release that was issued earlier this morning is a schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release.
Before I get into the results, let me remind you that some of the statements made during this review may be considered forward-looking statements. The 10-K for the fiscal year 2012 identifies certain factors that could cause the Company's actual results to differ materially from those projected in any forward-looking statements made today. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments. The 10-K is available through the Company and online.
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the press release and on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
Now, I would like to review our results for the third quarter of 2013. If you would refer to your copy of the press release, let's begin with the schedule titled, Supplementary Sales Data by Geographic Area. Worldwide sales to customers were $17.6 billion for the third quarter of 2013, up 3.1% as compared to the third quarter of 2012. On an operational basis, sales were up 4.7% and currency had a negative impact of 1.6%.